Precision’s Messerschmidt Discusses New Myeloma Therapies in Managed Healthcare Executive
In the current edition of Managed Healthcare Executive, Precision Oncology’s chief medical officer Dr. Gerry Messerschmidt comments on the unprecedented pace of outcomes improvements. (more…)
Precision’s Shafrin Writes of the Value of Real-World Evidence in Drug Discovery & Development
In a new article for Drug Discovery & Development, Precision Health Economics senior research economist Jason Shafrin addresses the use of real-world evidence, why we need it and how to effectively implement it. (more…)
POLITICO Pulses on Launch of IVI’s New Open-Source Value Tool
Must-read morning briefing POLITICO Pulse talks with Innovation & Value Initiative (IVI) executive director Darius Lakdawalla on the launch of a first-of-its-kind open-source project for determining the value of medical treatments. (more…)
Schafer in MedCity News: State-by-State Drug Pricing Regulations Will Bring Widespread Impact
Precision for Value’s Jeremy Schafer discusses the impact of new and proposed state legislation on drug pricing with MedCity News. According to Schafer, new policies could present challenges for manufacturers in evolving their pricing strategies. (more…)
Precision Value & Health Announces Formation of Global Market Access Consultancy—Precision Xtract
NEW ALIGNMENT OF INDUSTRY-LEADING CONSULTING AND DATA SERVICES PROVIDES UNIFIED HEALTH ECONOMICS AND OUTCOMES RESEARCH, PRICING, GLOBAL MARKET ACCESS, AND PAYER ANALYTICS TO SUPPORT PHARMACEUTICAL AND LIFE SCIENCES INNOVATORS
New York, NY – November 2, 2017 – Precision Value & Health today announced the formation of Precision Xtract—a new, focused alignment of the company’s global market access consulting and data services. The move is designed to offer clients an interconnected team of specialists developing strategies, tools, and tactics in support of next generation approaches to drug development and product value demonstration.